Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence ...

Kisqali (ribociclib) + endocrine therapy (ET) reduces recurrence risk by 28.5% beyond 3 years in HR+/HER2- early breast cancer, with consistent iDFS benefits across subgroups, including node-negative disease. Safety aligns with prior findings, and FDA action is expected in Q3.